Hunter sufferers will be benefited by the addition of an effective prostate cancer drug to the pharmaceutical benefits scheme.
The drug Zytiga will be subsidised by the government from next month and will take less of a toll on sufferer's wallets.
"Any advancement with the support financially of taking the modern drugs allocated [and] prescribed by doctors and specialist doctors in this field is much appreciated by the whole community, I'm sure," he said.
Zytiga is currently being hailed as one of the most important developments in prostate cancer treatment.
University of Newcastle Professor of Radiation Oncology, Jim Denham said the cheaper drug will provide an effective option to sufferers who are unable to use other therapies.
"[It] is useful after hormone therapy stops working for prostate cancer."
The drug will also offer better quality of life to users.
